115822-61-2

Basic information

• Product Name: 2H-CHROMEN-3-YLMETHANOL
• Synonyms: 2H-CHROMEN-3-YLMETHANOL;RARECHEM AL BD 1212;2H-chromen-3-ylmethanol, 90+%
• CAS NO: 115822-61-2
• Molecular Formula: C10H10O2
• Molecular Weight: 162.19
• Mol File: 115822-61-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 314.3 °C at 760 mmHg
• Flash Point: 150.7 °C
• Appearance: /
• Density: 1.182 g/cm³
• Vapor Pressure: 0.0002mmHg at 25°C
• Refractive Index: 1.583
• CAS DataBase Reference: 2H-CHROMEN-3-YLMETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-CHROMEN-3-YLMETHANOL(115822-61-2)
• EPA Substance Registry System: 2H-CHROMEN-3-YLMETHANOL(115822-61-2)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 115822-61-2(Hazardous Substances Data)

Usage

General Description

2H-Chromen-3-ylmethanol is a chemical compound belonging to the chromen class of organic compounds. It is a colorless liquid that is used in the synthesis of various pharmaceuticals and industrial products. Its structure contains a chromen ring with a hydroxymethyl group attached at the 3 position, making it an important building block in synthetic chemistry. 2H-Chromen-3-ylmethanol has potential applications in drug discovery and development as well as in the manufacturing of specialty chemicals. Additionally, it exhibits biological activities such as antioxidant and anti-inflammatory properties, making it a promising candidate for further research and development in the pharmaceutical industry.

InChI:InChI=1/C10H10O2/c11-6-8-5-9-3-1-2-4-10(9)12-7-8/h1-5,11H,6-7H2

Upstream product

• 22649-28-1 2H-chromene-3-carboxylic acid 
• 57543-66-5 2H-chromene-3-carbonitrile 
• 90-02-8 salicylaldehyde 
• 51593-69-2 2H-chromene-3-carbaldehyde 

Downstream Products

• 944903-95-1 chromane-3-carbaldehyde 
• 76727-28-1 hydroxymethyl-3 chromanne 

Relevant articles and documents

Dianionic Phase-Transfer Catalyst for Asymmetric Fluoro-cyclization

Inspired by the dicationic nature of the electrophilic fluorinating reagent, Selectfluor (1), we rationally designed a series of dicarboxylic acid precatalysts (2), which, when deprotonated, act as anionic phase-transfer catalysts for asymmetric fluorination of alkenes. Among them, 2a having the shortest linker moiety efficiently catalyzed unprecedented 6-endo-fluoro-cyclization of various allylic amides, affording fluorinated dihydrooxazine compounds with high enantioselectivity (up to 99% ee). In addition to cyclic substrates, acyclic trisubstituted alkenes underwent the reaction with good diastereoselectivity, whereas low diastereoselectivity was observed for linear disubstituted alkenes. Results suggest that the reaction proceeds via a fluoro-carbocation intermediate.

TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS

The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

Pharmacomodulation d'adrenolytiques α en serie benzopyrannique

Pharmacomodulation of α-adrenergic blocking agents by a series of benzopyrans.The N-methylpiperidine fragment was associated with four oxygenated heterocycles of the benzopyran ring system.Two different synthesis pathways were used in each case.Twenty intermediate derivatives and four aminomethylated derivatives whose structures were established by spectroscopic data are described.The pharmacological investigation demonstrates the interest of these compounds on the α-adrenergic receptors in light of their activities and selectivities. α1-adrenergic blocking agents / α2-adrenergic blocking agents / piperidinomethyl chromone, chromene and chromane